NASDAQ:BMRN BioMarin Pharmaceutical - BMRN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $90.98 -1.10 (-1.19%) (As of 03/22/2023 02:33 PM ET) Add Compare Share Share Today's Range$90.57▼$92.2550-Day Range$87.74▼$117.2752-Week Range$70.73▼$117.77Volume382,258 shsAverage Volume1.59 million shsMarket Capitalization$16.97 billionP/E Ratio122.95Dividend YieldN/APrice Target$120.11 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability BioMarin Pharmaceutical MarketRank™ ForecastAnalyst RatingModerate Buy2.61 Rating ScoreUpside/Downside30.3% Upside$118.15 Price TargetShort InterestBearish3.99% of Float Sold ShortDividend StrengthN/ASustainability-2.93Upright™ Environmental ScoreNews Sentiment0.94Based on 12 Articles This WeekInsider TradingSelling Shares$12.61 M Sold Last QuarterProj. Earnings Growth164.10%From $1.17 to $3.09 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.76 out of 5 starsMedical Sector79th out of 983 stocksPharmaceutical Preparations Industry23rd out of 478 stocks 4.3 Analyst's Opinion Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 2.53, and is based on 11 buy ratings, 7 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $118.15, BioMarin Pharmaceutical has a forecasted upside of 30.3% from its current price of $90.70.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.99% of the float of BioMarin Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 7.85%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioMarin Pharmaceutical has received a 35.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Galsulfase", "Laronidase", and "Cerliponase alfa" products. See details.Environmental SustainabilityThe Environmental Impact score for BioMarin Pharmaceutical is -2.93. Previous Next 3.3 News and Social Media Coverage News SentimentBioMarin Pharmaceutical has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for BioMarin Pharmaceutical this week, compared to 4 articles on an average week.Search InterestOnly 37 people have searched for BMRN on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.MarketBeat Follows4 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,607,900.00 in company stock.Percentage Held by InsidersOnly 1.75% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions96.26% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 164.10% in the coming year, from $1.17 to $3.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 122.57, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 118.83.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 122.57, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 88.04.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 3.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioMarin Pharmaceutical (NASDAQ:BMRN) StockBioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.Read More Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRN Stock News HeadlinesMarch 21, 2023 | marketbeat.comWhy did Sarepta Therapeutics Stock Plummet? (BMRN)SRPT stock fell 20% after the FDA changed course on their new DMD treatment approval. The stock remains strong with an encouraging outlook and a mod Buy rating.March 21, 2023 | finance.yahoo.comBioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74March 22, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.March 17, 2023 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime Sells 15,000 SharesMarch 16, 2023 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Receives $120.67 Consensus Price Target from BrokeragesMarch 16, 2023 | americanbankingnews.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Sees Significant Growth in Short InterestMarch 16, 2023 | americanbankingnews.comJean Jacques Bienaime Sells 8,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) StockMarch 14, 2023 | finance.yahoo.comBioMarin to Share Updated Data at 2023 American College of Medical Genetics and Genomics (ACMG) Meeting Demonstrating Commitment to Understanding Long-Term Benefit of VOXZOGO® in Children with AchondroplasiaMarch 22, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 8, 2023 | msn.comIs the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock?March 7, 2023 | finance.yahoo.comFDA now set to decide on BioMarin’s hemophilia drug by June 30March 7, 2023 | finance.yahoo.comU.S. FDA extends review of BioMarin's bleeding disorder therapyMarch 7, 2023 | finance.yahoo.comFDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5March 7, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), UnitedHealth (UNH) and Haleon PLC Sponsored ADR (HLN)March 6, 2023 | finance.yahoo.comWhy BioMarin Shares Are Plunging Today?March 6, 2023 | finance.yahoo.comBioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia AMarch 6, 2023 | finance.yahoo.comIs BioMarin Pharmaceutical (BMRN) an Attractive Investment?March 2, 2023 | finance.yahoo.comBioMarin to Participate in Three Investor Conferences in MarchMarch 1, 2023 | finance.yahoo.comBioMarin Pharmaceutical Full Year 2022 Earnings: EPS Beats ExpectationsFebruary 28, 2023 | finance.yahoo.comBioMarin (BMRN) Q4 Earnings Miss, Sales Beat, Stock DownFebruary 28, 2023 | finance.yahoo.comBioMarin Hints Probable Delay For US Approval For Roctavian, But Analyst Convinced For Transformative 2023February 28, 2023 | finance.yahoo.comQ4 2022 Biomarin Pharmaceutical Inc Earnings CallFebruary 28, 2023 | markets.businessinsider.comMorgan Stanley Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)February 28, 2023 | finance.yahoo.comCompared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key MetricsFebruary 27, 2023 | finance.yahoo.comBioMarin Pharmaceutical (BMRN) Q4 Earnings Lag EstimatesFebruary 27, 2023 | finance.yahoo.comBioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme BusinessFebruary 27, 2023 | finance.yahoo.comHere's How BioMarin Stock Looks Ahead of EarningsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address BMRN Company Calendar Last Earnings10/26/2021Today3/22/2023Next Earnings (Estimated)4/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:BMRN CUSIP09061G10 CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,082Year Founded1997Price Target and Rating Average Stock Price Forecast$118.15 High Stock Price Forecast$200.00 Low Stock Price Forecast$74.00 Forecasted Upside/Downside+30.4%Consensus RatingModerate Buy Rating Score (0-4)2.61 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)$0.74 Trailing P/E Ratio124.43 Forward P/E Ratio78.70 P/E GrowthN/ANet Income$141.56 million Net Margins6.75% Pretax Margin7.14% Return on Equity3.73% Return on Assets2.71% Debt Debt-to-Equity Ratio0.24 Current Ratio4.67 Quick Ratio3.15 Sales & Book Value Annual Sales$2.10 billion Price / Sales8.19 Cash Flow$1.48 per share Price / Cash Flow62.22 Book Value$24.82 per share Price / Book3.71Miscellaneous Outstanding Shares186,530,000Free Float183,265,000Market Cap$17.18 billion OptionableOptionable Beta0.39 Social Links Key ExecutivesJean-Jacques BienaiméChairman & Chief Executive OfficerBrian R. MuellerChief Financial Officer & Executive VP-FinanceEduardo E. von PervieuxChief Information OfficerHenry J. FuchsPresident-Worldwide Research & DevelopmentKevin EgganGroup VP, Head-Research & Early DevelopmentKey CompetitorsUnited TherapeuticsNASDAQ:UTHRAlnylam PharmaceuticalsNASDAQ:ALNYIonis PharmaceuticalsNASDAQ:IONSAlkermesNASDAQ:ALKSMadrigal PharmaceuticalsNASDAQ:MDGLView All CompetitorsInsiders & InstitutionsB. Riley Wealth Advisors Inc.Bought 2,622 shares on 3/15/2023Ownership: 0.001%Jean Jacques BienaimeSold 8,000 sharesTotal: $723,600.00 ($90.45/share)Victory Capital Management Inc.Bought 19,855 shares on 3/10/2023Ownership: 0.405%Jean Jacques BienaimeSold 15,000 sharesTotal: $1.38 M ($92.28/share)Rockefeller Capital Management L.P.Sold 492,384 shares on 3/6/2023Ownership: 0.283%View All Insider TransactionsView All Institutional Transactions BMRN Stock - Frequently Asked Questions Should I buy or sell BioMarin Pharmaceutical stock right now? 19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 1 sell rating, 7 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BMRN shares. View BMRN analyst ratings or view top-rated stocks. What is BioMarin Pharmaceutical's stock price forecast for 2023? 19 Wall Street research analysts have issued 1 year price objectives for BioMarin Pharmaceutical's shares. Their BMRN share price forecasts range from $74.00 to $200.00. On average, they anticipate the company's share price to reach $118.15 in the next year. This suggests a possible upside of 28.3% from the stock's current price. View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts. How have BMRN shares performed in 2023? BioMarin Pharmaceutical's stock was trading at $103.49 on January 1st, 2023. Since then, BMRN shares have decreased by 11.0% and is now trading at $92.08. View the best growth stocks for 2023 here. Are investors shorting BioMarin Pharmaceutical? BioMarin Pharmaceutical saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 7,280,000 shares, an increase of 7.9% from the February 13th total of 6,750,000 shares. Based on an average daily volume of 1,490,000 shares, the short-interest ratio is currently 4.9 days. Approximately 4.0% of the company's shares are sold short. View BioMarin Pharmaceutical's Short Interest. When is BioMarin Pharmaceutical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023. View our BMRN earnings forecast. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its quarterly earnings data on Tuesday, October, 26th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.05. The biotechnology company had revenue of $408.74 million for the quarter, compared to the consensus estimate of $435.29 million. BioMarin Pharmaceutical had a trailing twelve-month return on equity of 3.73% and a net margin of 6.75%. The business's revenue was down 14.3% compared to the same quarter last year. During the same period last year, the firm posted $0.29 earnings per share. What ETFs hold BioMarin Pharmaceutical's stock? ETFs with the largest weight of BioMarin Pharmaceutical (NASDAQ:BMRN) stock in their portfolio include Invesco Dynamic Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), VanEck Biotech ETF (BBH), First Trust NYSE Arca Biotechnology Index Fund (FBT), Goldman Sachs Future Health Care Equity ETF (GDOC), WisdomTree U.S. Growth & Momentum Fund (WGRO), VictoryShares Nasdaq Next 50 ETF (QQQN) and BlackRock Future Health ETF (BMED). What guidance has BioMarin Pharmaceutical issued on next quarter's earnings? BioMarin Pharmaceutical issued an update on its FY 2023 earnings guidance on Monday, February, 27th. The company provided EPS guidance of $1.80-$2.05 for the period, compared to the consensus EPS estimate of $1.61. The company issued revenue guidance of $2.38 billion-$2.50 billion, compared to the consensus revenue estimate of $2.58 billion. What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO? 228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX). What is BioMarin Pharmaceutical's stock symbol? BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN." Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional investors include Norges Bank (1.48%), Geode Capital Management LLC (1.39%), Parnassus Investments LLC (1.26%), Charles Schwab Investment Management Inc. (0.67%), California Public Employees Retirement System (0.66%) and Legal & General Group Plc (0.63%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, David E I Pyott, Dennis Slamon, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Michael G Grey, Richard A Meier, V Bryan Lawlis and Willard H Dere. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioMarin Pharmaceutical's stock price today? One share of BMRN stock can currently be purchased for approximately $92.08. How much money does BioMarin Pharmaceutical make? BioMarin Pharmaceutical (NASDAQ:BMRN) has a market capitalization of $17.18 billion and generates $2.10 billion in revenue each year. The biotechnology company earns $141.56 million in net income (profit) each year or $0.74 on an earnings per share basis. How many employees does BioMarin Pharmaceutical have? The company employs 3,082 workers across the globe. How can I contact BioMarin Pharmaceutical? BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The official website for the company is www.bmrn.com. The biotechnology company can be reached via phone at (415) 506-6700, via email at ir@bmrn.com, or via fax at 415-382-7889. This page (NASDAQ:BMRN) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.